This company has been marked as potentially delisted and may not be actively trading. Talaris Therapeutics (TALS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsDividendInsider TradesTrendsBuy This Stock TALS vs. IMVT, IBRX, VCEL, BCRX, DNLI, KYMR, TWST, CGON, BEAM, and RXRXShould you be buying Talaris Therapeutics stock or one of its competitors? The main competitors of Talaris Therapeutics include Immunovant (IMVT), ImmunityBio (IBRX), Vericel (VCEL), BioCryst Pharmaceuticals (BCRX), Denali Therapeutics (DNLI), Kymera Therapeutics (KYMR), Twist Bioscience (TWST), CG Oncology (CGON), Beam Therapeutics (BEAM), and Recursion Pharmaceuticals (RXRX). These companies are all part of the "biological products, except diagnostic" industry. Talaris Therapeutics vs. Immunovant ImmunityBio Vericel BioCryst Pharmaceuticals Denali Therapeutics Kymera Therapeutics Twist Bioscience CG Oncology Beam Therapeutics Recursion Pharmaceuticals Talaris Therapeutics (NASDAQ:TALS) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation, institutional ownership and community ranking. Which has more volatility & risk, TALS or IMVT? Talaris Therapeutics has a beta of 2.18, meaning that its share price is 118% more volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Does the MarketBeat Community favor TALS or IMVT? Immunovant received 119 more outperform votes than Talaris Therapeutics when rated by MarketBeat users. Likewise, 77.65% of users gave Immunovant an outperform vote while only 48.15% of users gave Talaris Therapeutics an outperform vote. CompanyUnderperformOutperformTalaris TherapeuticsOutperform Votes1348.15% Underperform Votes1451.85% ImmunovantOutperform Votes13277.65% Underperform Votes3822.35% Which has stronger valuation & earnings, TALS or IMVT? Talaris Therapeutics is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTalaris TherapeuticsN/AN/A-$73.89M-$1.79-8.44ImmunovantN/AN/A-$259.34M-$2.62-5.45 Do institutionals & insiders have more ownership in TALS or IMVT? 67.6% of Talaris Therapeutics shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 16.5% of Talaris Therapeutics shares are owned by insiders. Comparatively, 5.9% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is TALS or IMVT more profitable? Talaris Therapeutics' return on equity of -39.93% beat Immunovant's return on equity.Company Net Margins Return on Equity Return on Assets Talaris TherapeuticsN/A -39.93% -37.37% Immunovant N/A -77.94%-69.82% Do analysts rate TALS or IMVT? Immunovant has a consensus target price of $38.33, suggesting a potential upside of 168.42%. Given Immunovant's stronger consensus rating and higher possible upside, analysts clearly believe Immunovant is more favorable than Talaris Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Talaris Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Immunovant 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.90 Does the media refer more to TALS or IMVT? In the previous week, Immunovant had 13 more articles in the media than Talaris Therapeutics. MarketBeat recorded 13 mentions for Immunovant and 0 mentions for Talaris Therapeutics. Immunovant's average media sentiment score of 1.48 beat Talaris Therapeutics' score of 0.00 indicating that Immunovant is being referred to more favorably in the news media. Company Overall Sentiment Talaris Therapeutics Neutral Immunovant Positive SummaryImmunovant beats Talaris Therapeutics on 9 of the 16 factors compared between the two stocks. Get Talaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TALS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TALS vs. The Competition Export to ExcelMetricTalaris TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$646.16M$2.91B$5.31B$8.42BDividend YieldN/A1.68%5.21%4.10%P/E Ratio-8.4430.9526.7819.69Price / SalesN/A397.63386.97118.34Price / CashN/A168.6838.2534.62Price / Book3.493.206.744.50Net Income-$73.89M-$72.35M$3.23B$248.32M Talaris Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TALSTalaris TherapeuticsN/A$15.11-6.7%N/A+11.3%$646.16MN/A-8.4484IMVTImmunovant2.7008 of 5 stars$14.02-3.6%$38.33+173.4%-52.4%$2.38BN/A-5.35120Positive NewsGap UpIBRXImmunityBio1.86 of 5 stars$2.51+6.4%$12.19+385.6%-61.1%$2.22B$14.75M-2.73590Analyst UpgradeHigh Trading VolumeVCELVericel2.5572 of 5 stars$43.64+2.3%$60.86+39.5%-20.3%$2.19B$238.54M727.45300News CoveragePositive NewsAnalyst ForecastBCRXBioCryst Pharmaceuticals4.616 of 5 stars$10.06-2.7%$16.56+64.6%+56.9%$2.11B$503.49M-16.49530Positive NewsAnalyst UpgradeHigh Trading VolumeDNLIDenali Therapeutics4.42 of 5 stars$14.26-3.6%$33.79+136.9%-31.5%$2.07B$330.53M-5.17430Analyst ForecastGap UpKYMRKymera Therapeutics2.7085 of 5 stars$31.14-3.2%$55.27+77.5%-14.7%$2.03B$47.07M-13.31170Analyst ForecastGap DownTWSTTwist Bioscience4.2972 of 5 stars$32.29-2.0%$50.40+56.1%-35.4%$1.97B$347.68M-9.55990Positive NewsCGONCG Oncology2.222 of 5 stars$24.18-3.9%$58.56+142.2%-9.5%$1.84B$1.14M-17.0361Analyst ForecastBEAMBeam Therapeutics3.1284 of 5 stars$18.05-1.0%$48.75+170.1%-30.6%$1.83B$63.58M-10.26510Positive NewsRXRXRecursion Pharmaceuticals2.4179 of 5 stars$4.51-2.8%$7.60+68.5%-57.0%$1.81B$59.82M-2.95400 Related Companies and Tools Related Companies Immunovant Alternatives ImmunityBio Alternatives Vericel Alternatives BioCryst Pharmaceuticals Alternatives Denali Therapeutics Alternatives Kymera Therapeutics Alternatives Twist Bioscience Alternatives CG Oncology Alternatives Beam Therapeutics Alternatives Recursion Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TALS) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredMemorial Day: 59% dividend from Bitcoin (No Crypto Needed)140% Dividends from stocks like Tesla? Discover How for Just $9! For Memorial Day, get the full details of ...Investors Alley | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredPrepare now for May 31 eventPrepare now for May 31 event Circle May 31 on your calendar This man grew up in a trailer in New Mexico. To...Stansberry Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredTrump Quietly Planning $15 Trillion Crypto ShockerMost investors are still unaware, but I believe a new White House action may have quietly opened the floodgate...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Talaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Talaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TALS Stock Free TALS Stock Alerts